Picture of Zhaoke Ophthalmology logo

6622 — Zhaoke Ophthalmology News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

China's Zhaoke jumps as US FDA accepts new drug application for myopia treatment

** Shares of Chinese ophthalmic drugs developer and
manufacturer Zhaoke Ophthalmology Ltd  6622.HK  jump as much as
16.3% to HK$3.36, their highest since May 18
    ** Extends gains for the fourth consecutive session
    ** Stock on course for its biggest one-day pct rise since
Jan. 16, if gains hold
    ** Guangdong-based Zhaoke says U.S. Food and Drug
Administration (FDA) has accepted for review the New Drug
Application for the company's lead compound NVK002 as a
potential treatment for myopia in children  
    ** NVK002 is a proprietary, investigational,
preservative-free eye drop to control myopia progression in
children and intended for patients between ages 3 and 17
    ** Co says in 2020 it entered into NVK002 License Agreement
with Nevakar Inc's Vyluma Inc to develop, manufacture, register,
import and commercialize NVK002 in Greater China, South Korea
and certain countries in Southeast Asia
    ** The Hang Seng Commerce & Industry Index  .HSNC  rises
1.2%, while the Hang Seng Composite Index  .HSCI  and the Hang
Seng Index  .HSI  both climb 1.1%
    ** As of last close, the stock had slid 4.3% this year

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))

Recent news on Zhaoke Ophthalmology

See all news